PD Dr. Jan Lehmann

2022

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data.
Eur Urol 81:50-61,2022
Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group

Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom: Ergebnisse der ProComD-Studie.
Urologe, 61:173-182,2022
Lehmann J, Kluike CW, Haider A, Haider KS, Baumann S, Flesch M, Gedamke M, Kägebein D.

2021

Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.
Eur J Cancer, 155:64-72,2021
Hiester A, Fingerhut A, Niegisch G, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Loy V, Wittekind C, Hartmann M, Albers P.

2019

A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer.
J Cancer Res Clin Oncol. 145:811-820,2019
Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Füssel S, Novotny V, Toma M, Gajda M, Lehmann J, Wunderlich H, Grimm MO, Stöckle M, Junker K

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Eur J Cancer. 107:37-45,2019
Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
Eur Urol. 75:604-611,2019
Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M

2018

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med. 378:1408-1418,2018
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN1, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.
Collaborators: Horvath L, Nott L, Mathlum M, Coward J, Ng S, Epstein R, Tran B, Guminski A, Bastick P, Pittman K, Tan H, Wei C, Kukard C, Nasser E, Parente P, Marx G, Krainer M, Loidl W, Hutterer G, Tombal B, Sautois B, Werbrouck P, Roumeguère T, Ameye F, Joniau S, Lumen N, Renaud P, North S, Chin J, Barkin J, Carmel M, Casey R, Gleave M, Klotz L, Ouellette P Jr, Eiley D, Hamilton R, Attwell A, Lacombe L, Wood L, Aaron L, Abdelsalam M, Canil C, Ellard S, Webster T, Reiman A, Flax S, Vrabec G, Bladou F, Donnelly B, Giddens J, Leung W, Shayegan B, Lukka H, Simard J, Zadra J, Archambault R, Melichar B, Stahalova V, Stanek R, Matouskova M, Pavlik I, Sochor M, Jarolím L, Zachoval M, Klecka J, Brasso K, Harving N, Holm-Nielsen A, Poulsen M, Taari K, Tammela T, Boström P, Ronkainen H, Marttila T, Vincendeau S, Berdah JF, Villers A, Pfister C, Flechon A, Mouillet G, Bompas E, Delva R, Joly F, Beuzeboc P, Eymard JC, Colombel M, Ferrero JM, Gravis G, Krakowski I, Voog E, Barthelemy P, Robert G, Priou F, Barry-Delongchamps N, Larré S, Theodore C, Azzouzi AR, Deville JL, Linassier C, Mahammedi H, Houédé N, Artignan X, Feyerabend S, Gleissner J, von Klot C, Stöckle M, van Essen J, Ritter M, Stenzl A, Grimm MO, Suttmann H, Rodemer G, Steuber T, Rudolph R, Tsaur I, Bögemann M, Klotz T, Thomas C, Reichle A, Huebner A, Koenig F, Spiegelhalder P, Bismarck E, Hellmis E, Carl S, Strauss A, Berse M, Kretz T, Zimmermann U, Hammerer P, Lehmann J, Geiges G, Machtens S, Katona F, Szilágyi L, Kulcsár D, Lakatos Á, Géczi L, Berger R, Sella A, Nativ O, Frank S, Rosenbaum E, Peer A, Keizman D, Stein A, Sarid D, Sternberg C, Bracarda S, Paglino C, Gallucci M, Alabiso O, Bertolini A, Cianci C, Ciuffreda L, Rocco F, De Giorgi U, Boccardo F, Cappuzzo F, Emarcora P, Battaglia M, Scagliotti G, Nolè F, Cicalese V, Sakai H, Tsunemori H, Maruyama S, Suzuki H, Kawano Y, Heshine K, Fukumori T, Mizokami A, Tamada S, Tsumura H, Tozawa K, Yamaguchi A, Arai G, Tsuchiya T, Matsubara A, Matsubara N, Furukawa J, Azumi M, Uemura H, Kinoshita H, Igawa T, Tanabe K, Kasahara T, Saito S, Sugimoto T, Iijima K, Matsumoto H, Narita S, Hara I, Kobayashi H, Takahashi A, de Wildt M, Beeker A, Hamberg P, Mulders P, Helgason H, Vergunst H, Roeleveld T, Beaven A, Gilling P, Buchan N, Nixon T, Angelsen A, Heinrich D, Zurawski B, Milecki P, Walaszkowska-Czyz A, Jassem J, Humanski P, Darewicz B, Pikiel J, Drewa T, Sosnowski M, Radziszewski P, Slojewski M, Zdrojowy R, Ciurescu D, Jinga V, Toganel C, Udrea A, Herzal A, Semenov A, Alekseev B, Ivanov S, Kopyltsov E, Kheyfets V, Varlamov S, Kovalenko R, Cheporov S, Karyakin O, Izmailov A, Kulikov E, Khvorostenko D, Gorelov A, Matveev V, Kopp M, Goncalves F, Sokol R, Kliment J, Knazik R, Brezovsky M, Chung BH, Lee HM, Choi YD, Ha HK, Kwak C, Byun SS, Kim CS, Kim CI, Kang TW, Moon G, Kwon TG, García-Donás J, Maroto JP, Arranz JA, Carles J, Castellano D, Perez Gracia JL, Iborra I, Barretina Ginesta MP, Font A, Gallardo E, Gonzalez del Alba A, Casinnello J, Rubio G, Gonzalez Larriba JL, Carballido J, Juarez A, Miñana B, Ribal MJ, Ferrer C, Angulo J, Rios Gonzalez E, Medina R, Chantada V, Guttierez JL, Sanchez E, Lara P, Llarena R, Gomez Veiga F, Damber JE, Häggman M, Widmark A, Andren O, Kjellman A, Wu T, Chung HJ, Wu HC, Ou YC, Chiang PH, Pang ST, Huang CY, Mills J, Jones R, McInerney P, Attard G, Malik Z, Pandha H, Mazhar D, Bottomley D, Button M, Beesley S, Nabi G, Sayers I, Parikh O, Crabb S, Wagstaff J, Falconer A, Aggarwal R, Shore N, Antonarakis ES, Liu G, Sieber P, Tutrone R Jr, Belkoff L, Hainsworth J, Higano C, Twardowski P, Rathkopf D, Given R, Karlin G, Lara P Jr, Nordquist L, Srinivas S, Dakhil S, Bracken RB, Westenfelder K, Frankel J, Brand T, Drakaki A, Sonpavde G, Tejwani S, Cook D, Israel A, Dato P, Perzin A, Williams T, Alter R, Gingrich J, Uchio E, Williams J, Zibelman M, Prasad S, Karsh L, Patsias G, Savage S, Van Veldhuizen P, Miller L, Pieczonka C, Kambhampati S, Deguenther M, Keller L III, Omarbasha B, Clark W, Bertram R, Saslawsky M, Hauke R, Myrick S, Ghaddar H, Foreno L, Forero G, Doshi G, Fleming M, Troner M, Shaffer D, Vogelzang N, Hirsch B, Schnadig I, Bailen J, Gittelman M, Goldfischer E, Fisher H, Grable M, Corn P, Lim E, Cosgriff T, Chu F, Acs P, Reeves J Jr, Stein M, Al-Janadi A, Siegel R, Patel K, Kella N, Willard TB, Gatrell B, Schiffman Z, Bidair M, Ornstein D, Bylow K, Agrawal M, Suh R, Busby JE, Bardot S, Taylor J, Wolk F, Courtney K, Vaishampayan U, Sharifi R, Hoimes C, Harris R, Nickols N, Rosales J, Wrenn J, Goueli B, Dorff T, Yee D, David R, Bianco F, Henry E, Jaslowski A, Mannuel H, Krejci K, Gervasi L, Clement J, Bernstein G, Somer B, Lipsitz D, Heron S, Nemoy N, Rosenberg S, Miller A, Shetty S, Weckstein D, Salazar M, Margolis E, Katz A, Renzuli J II, Tan W, Van Echo D, Haluschak J, Showel J, Schmidt W Jr, Sharma S, Hancock M, Morris D, Tebyani N, Armas A, Tarter T, Balaji KC, Franks M, Williams R, Snoy F, Pachynski R, Ahaghotu C, Kemeny M

2017

Kosteneffektivität von GnRH-Antagonisten bei Patienten mit Prostatakarzinom und kardiovaskulärem Risiko.
Urologe 56:917-924,2017
Anderson D, Lehmann J, Ecker T, Vosgerau S, Donatz V

2016

Auswirkungen geänderter Einschlusskriterien und negativer Berichterstattung zum PSAScreening auf die Zahl potentiell für die PREFERE-Studie rekrutierbarer Patienten.
Urologe 55:1213-7,2016
Mathes J, Burger M, Gschwend JE, Hakenberg OW, Krege S, Lehmann J, Miller K, Roigas J, Roth S, Kälble T

2015

Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.
J Cancer Res Clin Oncol. 141:1779-1790,2015
Rogler A, Kendziorra E, Giedl J, Stoehr C, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R

Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients.
Mol Med. 21:371-380,2015
Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A

2014

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.
BMC Cancer. 14:214,2014
Rogler A, Hoja S, Giedl J, Ekici AB, Wach S, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R

2013

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy.
BMC Cancer 13:71,2013
Keck B, Wach S, Stoehr R, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A

Fast-track rehabilitation after robot-assisted laparoscopic cystectomy accelerates postoperative recovery.
BJU Int 112:E99-106,2013
Saar M, Ohlmann CH, Siemer S, Lehmann J, Becker F, Stöckle M, Kamradt J

SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.
Ann Surg Oncol 20:3669-3674,2013
Keck B, Wach S, Goebell PJ, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A

Stellenwert der intermittierenden Androgendeprivation im Kontext der aktuellen Datenlage.
Aktuelle Urol 44:271-276, 2013
Miller K, Hammerer P, Eichenauer R, Geiges G, Lehmann J, Rodemer G, Ruessel C, Rulf W, Suttmann H, Wolff JM

Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder.
Ann Surg Oncol 20:2440-2445,2013
Keck B, Wach S, Kunath F, Bertz S, Taubert H, Lehmann J, Stöckle M, Wullich B, Hartmann A

2011

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.
Lancet Oncol. 12:137-143, 2011
Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, Fradet Y, Lehmann J, Stöckle M, Hartmann A, Lee JK, Theodorescu D

Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow.
Eur Urol. 60:231-238, 2011
Retz M, Rotering J, Nawroth R, Buchner A, Stöckle M, Gschwend JE, Lehmann J

Increased expression of transcription factor TFAP2 correlates with chemosensitivity in advanced bladder cancer.
BMC Cancer. 11:135, 2011
Nordentoft I, Dyrskjt L, Bdker JS, Wild PJ, Hartmann A, Bertz S, Lehmann J, Orntoft TF, Birkenkamp-Demtroder K

The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma.
Int J Cancer. 129:346-354, 2011
Keck B, Stoehr R, Wach S, Rogler A, Hofstaedter F, Lehmann J, Montironi R, Sibonye M, Fritsche HM, Lopez-Beltran A, Epstein JI, Wullich B, Hartmann A

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Ann Oncol. 22:288-294, 2011
Albers P, Park SI, Niegisch G, Fechner G, Steiner U, Lehmann J, Heimbach D, Heidenreich A, Fimmers R, Siener R; AUO Bladder Cancer Group

2010

Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society.
Urol Int 85:1-10, 2010
Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, Krege S, Lehmann J, Rohde D, Schmidberger H, Uder M, Zeeb H

EMMPRIN (CD147) Ein prognostischer und potenzieller therapeutischer Marker im Urothelkarzinom.
Pathologe Suppl 2, 251-254, 2010
Nawroth R, Hartmann A, Wild P, Lehmann J, Stöhr R, Gschwend JE, Retz M

Phase II study of the human anti-epithelial cell adhesion molecule antibody Adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Urol Int 85:386-395, 2010
Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Bäuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
Neoplasia 12:628-636, 2010
Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Schuler M, Hartmann A

Vinflunin in der Zweitlinienbehandlung des Urothelkarzinoms.
Der Onkologe 16:523-526, 2011
J. Lehmann

2009

Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).
Eur Urol 55:1293-1299, 2009
Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M

Chemotherapie des Harnblasenkarzinoms - Neuigkeiten 2009.
Urologe 48:655-662, 2009
Retz M, Gschwend JE, Lehmann J

Das Ausmaß der Lymphadenektomie im Rahmen der radikalen Zystektomie - Fallstricke bei der Interpretation aktueller Studienergebnisse.
Urologe. 48:151-155, 2009
Suttmann H, Kamradt J, Becker F, Lehmann J, Stöckle M

Ergebnisse der randomisierten Phase-III-Studie der German Testicular Cancer Study Group Retroperitoneale Lymphadenektomie vs. 1 Zyklus PEB als adjuvante Therapie beim nichtseminomatösen Hodentumor im klinischen Stadium I.
Urologe 48:523-528, 2009
Hartmann M, Siener R, Krege S, Schmelz H, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Albers P; German Testicular Cancer Study Group

Urothelkarzinom - Ursachen und Risikofaktoren.
Uro-News: 49-54, 5/2009
Lehmann J

Metastasenchirurgie in kurativer Absicht beim Urothelkarzinom.
Urologe 48:143-150, 2009
Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M

2008

[18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial.
Ann Oncol 19:1619-1623, 2008
de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, Franzius C, Kliesch S, Schlemmer M, Tatsch K, Heicappell R, Geworski L, Amthauer H, Dohmen BM, Schirrmeister H, Cremerius U, Bokemeyer C, Bares R:

Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer.
Int J Cancer 122:2422–2428, 2008
Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, Alken P, Coy JF

Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure.
Int J Urol. 15:407-415, 2008
Schulte-Baukloh H, Bigalke H, Miller K, Heine G, Pape D, Lehmann J, Knispel HH:

Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience.
Cancer Biother Radiopharm. 23:609-618, 2008
Suttmann H, Grgic A, Lehmann J, Zwergel U, Kamradt J, Gouverneur E, Pinkert J, Stöckle M, Kirsch CM, Nestle U

Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells.
BMC Urol. 8:5, 2008
Suttmann H, Retz M, Paulsen F, Harder J, Zwergel U, Kamradt J, Wullich B, Unteregger G, Stöckle M, Lehmann J

Medikamentöse Tumortherapie: Urothelkarzinom Fortschritte in der Neoadjuvanz, Adjuvanz und Palliation.
Uro-News: 39-46, 6/2008
Lehmann J

2007

Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival.
Eur Urol 51:1281-1288, 2007
Lehmann J, Suttmann H, Kovac I, Hack M, Kamradt J, Siemer S, Wullich B, Zwergel U, Stöckle M

Therapie und Prognose des lymphogen metastasierten Harnblasenkarzinoms.
Deutsches Ärzteblatt 104:959-963, 2007
Stöckle M, Lehmann J, Krege S, Gschwend JE, Otto T, Rübben H

Metastasiertes Harnblasenkarzinom.
Deutsches Ärzteblatt 104:1024-1028, 2007
Jakse G, Stöckle M, Lehmann J, Otto T, Krege S, Rübben H

Improving the prognosis of patients after radical cystectomy. Part I: the role of lymph node dissection.
BJU Int. 100:1221-1224, 2007
Suttmann H, Kamradt J, Lehmann J, Stöckle M

Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy.
BJU Int. 100:1225-1228, 2007
Suttmann H, Kamradt J, Lehmann J, Stöckle M

Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy.
Eur Urol. 52:1058-1065, 2007
Zwergel U, Suttmann H, Schröder T, Siemer S, Wullich B, Kamradt J, Lehmann J, Stöckle M

2006

Complete longterm survival data from a trial on adjuvant chemotherapy versus control after radical cystectomy for locally advanced bladder cancer.
BJU Int 97:42-47, 2006
Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M

Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cells.
Eur Urol 50:141-147, 2006
Lehmann J, Retz M, Sidhu SS, Suttmann H, Sell M, Paulsen F, Harder J, Unteregger G, Stöckle M

Long-term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma a case report.
Int J Urol  13:1035-1036, 2006
Lehmann J, Retz M, Siemer S, Rotering J, Hack M, Schreier U, Zwergel U, Stöckle M

Die Expression des antimikrobiellen Peptides MUC7 in der Pyelonephritis.
Urologe 45:1300-1307, 2006
Lehmann J, Retz M, Siemer S, Shayesteh-Kheslat R, Hack M, Stöckle M

Systemic chemotherapy for advanced transitional cell carcinoma: A critical analysis. In Trends in chemotherapy research. Weber MD (Hrsg.)
Nova Science Publishers, Inc., 2006 (ISBN: 1-59454-353-4)
Lehmann J, Retz M, Stöckle M

A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
Ann Oncol 17:1533-1538, 2006
von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough J, Chen G, Kania M

Phase II trial of adjuvant gemcitabine plus cisplatin with amifostine cytoprotection in patients with locally advanced bladder cancer.
Clin Genitourin Cancer 5:150-154, 2006
Jin JO, Lehmann J, Taxy J, Huo D, Stöckle M, Steinberg G, Stadler W

Protein Profiling of Bladder Cancer Using the 2D-PAGE and SELDI-TOF-MS Technique.
Technol Cancer Res Treat 5:67-72, 2006
Langbein S, Lehmann J, Harder A, Steidler A, Michel MS, Alken P, Badawi JK

2005

Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
J Clin Oncol 23:4963-4974, 2005
Lehmann J, Retz M, Wiemers C, Beck J, Throff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M

Lehmann J, Retz M, Stöckle M: Systemische Chemotherapie des metastasierten Urothelkarzinoms eine kritische Analyse; in Blasenkarzinom Neue Perspektiven in Diagnostik und Behandlung.
Lehmann J, Retz M, Stöckle M (Hrsg).
Springer Medizin Verlag Heidelberg, 2005 (ISBN: 3-540-20504-7)

Retz M, Lehmann J: Molekulare Prognosemarker des Harnblasenkarzinoms; in Blasenkarzinom Neue Perspektiven in Diagnostik und Behandlung.
Lehmann J, Retz M, Stöckle M (Hrsg).
Springer Medizin Verlag Heidelberg, 2005 (ISBN: 3-540-20504-7)

Stöckle M, Lehmann J: Das kontrovers diskutierte Tumorstadium pT1G3; in Blasenkarzinom Neue Perspektiven in Diagnostik und Behandlung.
Lehmann J, Retz M, Stöckle M (Hrsg).
Springer Medizin Verlag Heidelberg, 2005 (ISBN: 3-540-20504-7)

Stöckle M, Lehmann J: Therapie und Prognose des lymphogen metastasierten Urothelkarzinoms- Stellenwert der Lymphknotenchirurgie und der perioperativen systemischen Chemotherapie; in Blasenkarzinom Neue Perspektiven in Diagnostik und Behandlung.
Lehmann J, Retz M, Stöckle M (Hrsg).
Springer Medizin Verlag Heidelberg, 2005 (ISBN: 3-540-20504-7)

Current TNM classification of renal cell carcinoma evaluated: revising stage T3a.
J Urol 173:33-37, 2005
Siemer S, Lehmann J, Loch A, Becker F, Stein U, Schneider G, Ziegler M, Stöckle M

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data.
Eur Urol 48:189-201, 2005
Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group

Systemische Therapie des fortgeschrittenen Urothelkarzinoms.
Der Onkologe 11:1210-1218, 2005
Lehmann J, Retz M, Stöckle M

Adjunktive systemische Chemotherapie des lokal fortgeschrittenen Urothelkarzinoms der Harnblase.
Journal ONKOLOGIE: 30-34, 5/2005
Lehmann J, Stöckle M

Systemische Chemotherapie des lokal fortgeschrittenen Harnblasenkarzinoms adjuvante Behandlung 2005 im Blickpunkt.
Uro-News: 35-37, 4/2005
Lehmann J

Studienlandschaft-Blasenkarzinom.
Urologe 44:1435-1438, 2005
Lehmann J, Böhle A

2004

The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Cancer 101:1552-1562, 2004
Lehmann J, Retz M, Nürnberg N, Schnöckel U, Raffenberg U, Krams M, Kellner U, Siemer S, Weichert-Jacobsen K, Stöckle M

Lehmann J, Stöckle M: Indication and results of adjuvant chemotherapy following radical cystectomy; in Current controversies in the management of genitourinary malignancies.
Heidenreich A, Hofmann R, Ravery V (Hrsg)
Sympomed Medical Publishers Taufkirchen /München, 2004 (ISBN: 3-927-75928-7)

Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR.
Eur Urol 43:314-319, 2004
Retz M, Lehmann J, Szysnik C, Zwank S, Venzke T, Wullich B, Röder C, Basbaum C, Stöckle M

Lymph node positive prostate cancer: long-term survival data after radical prostatectomy.
J Urol 171:1128-1131, 2004
Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Zwergel T, Stöckle M

Prenatal diagnosis of congenital mesoblastic nephroma associated with renal hypertension in a premature child.
Int J Urol 11:50-52, 2004
Siemer S, Lehmann J, Reinhard H, Graf N, Löffler G, Hendrik H, Remberger K, Stöckle M

Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy.
J Urol 171:2155-2159, 2004
Siemer S, Lehmann J, Kamradt J, Loch T, Remberger K, Humke U, Ziegler M, Stöckle M 

2003

Die medizinische Versorgung der Toreros in Spanien.
Zentralbl Chir 128:685-90, 2003
Lehmann V, Lehmann J

Gemcitabin/Cisplatin versus MVAC 5-Jahres Ergebnisse der Phase III Studie zur Chemotherapie des fortgeschrittenen Urothelkarzinoms in Deutschland.
UrologeA 42:1074-1086, 2003
Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M

Gemcitabin in der Behandlung des fortgeschrittenen Urothelkarzinoms.
UrologeA 42:63-77, 2003
Lehmann J, Retz M, Lippert C, Albers P, Stöckle M

Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial.
Crit Rev Hemat Oncol 47:171-179, 2003
Lehmann J, Retz M, Stöckle M

Systemische Chemotherapie des Urothelkarzinoms.
Onkologie 26(suppl 4):18-25, 2003
Lehmann J, Retz, M, Hack M, Siemer S, Stöckle M

Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor.
J Urol 169:86-89, 2003
Retz M, Lehmann J, Amann E, Wullich B, Röder C, Stöckle M

2002

Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection.
BMC Infect Dis 2:20, 2002
Lehmann J, Retz M, Harder J, Krams M, Kellner U, Hartmann J, Hohgräve K, Raffenberg U, Gerber M, Loch T, Weichert-Jacobsen K, Stöckle M

Managing locally advanced bladder cancer.
Expert Rev Anticancer Ther 2:656-666, 2002
Lehmann J, Retz M, Siemer S, Kamradt J, Wullich B, Stöckle M

Chemotherapy in the post-MVAC era, the case for adjuvant chemotherapy.
World J Urol 20:144-150, 2002
Lehmann J, Retz M, Stöckle M

Age dependent secretion of LH and ACTH in healthy men and patients with erectile dysfunction.
European Urology 41:144-153, 2002
Derouet H, Lehmann J, Stamm B, Lühl C, Römer D, Georg T, Isenberg E, Gebhardt T, Stöckle M

Interdisziplinäres Therapiemanagement urogenitaler Rhabdomyosarkome im Kindesalter.
Aktuelle Urologie 33:442-447, 2002
Siemer S, Lehmann J, Humke U, Krenn T, Reinhard H, Graf N, Venzke T, Schneider G, Loch T, Stöckle M

2001

Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients.
Eur Urol 39:507-517, 2001
Retz M, Lehmann J, Röder C, Weichert-Jacobsen K, Loch T, Romahn E, Lühl C, Kalthoff H, Stöckle M

Nachsorge des Harnblasenkarzinoms.
UrologeA 40:480-484, 2001
Retz M, Lehmann J, Wullich B, Stöckle M

2000

Retroperitoneal mature teratoma fifteen years after initial treatment of testicular mixed germ cell tumor - a case report.
Eur Urol 38:594-598, 2000
Lehmann J, Retz M, Nürnberg N, Romahn E, Küppers F, Loch T, Stöckle M

A hypoechoic lesion found on testicular ultrasound after testicular piercing.
J Urol 164:1651, 2000 
Lehmann J, Jancke C, Retz M, Loch T, Küppers F, Stöckle M, Weichert-Jacobsen K

Long-term followup of combined radiochemotherapy for locally advanced bladder cancer.
Cancer 89:1089-1094, 2000
Retz M, Lehmann J, Trocha C, Loch T, Seppelt U, Fischer C, Pinkenburg F, Timm KJ, Wellek S, Stöckle M

1999

Systemische Chemotherapie des Harnblasenkarzinoms - Fakten und Entwicklungen seit 1998.
UrologeB 39:317-320, 1999
Retz M, Lehmann J, Stöckle M

1998

Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma.
Cancer Res 58:5662-5666, 1998
Retz M, Lehmann J, Röder C, Plötz B, Harder J, Eggers J, Pauluschke J, Kalthoff H, Stöckle M

Lokal fortgeschrittenes Urothelkarzinom der Harnblase. Was ist gesichert in der Uroonkologie.
UrologeB 38:337-339, 1998
Retz M, Lehmann J, Stöckle M

1997

Young investigator award presentation at the 13th annual meeting of the ESMRMB, September 1996 Prag: Quantification of pulmonary water compartments by magnetic resonance.
MAGMA 5: 3-11, 1997
Lehmann J, Böck JC, Podrabsky P, Wlodarczyk W, Felix R

Kernspinangiographische Darstellung der experimentellen Lungenarterienembolie mit Hilfe eines makromolekularen Kontrastmittels.
Röntgen Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 167: 516-520, 1997
Böck JC, Lehmann J